Subtype
Primary Central Nervous System Neoplasm
CI-CAN-00001432Explore in graph →
Non-malignant957 active trials5 approved drugs175 evidence items
- NCIt
- C102871
Loading cancer entity…
Subtype
CI-CAN-00001432Explore in graph →
Clinical trials
3,294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06888817 | Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases(BRAINS) | recruiting | Phase 3 | 408 | The Netherlands Cancer InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07698457 | Clinical Benefit of 18F-FET in Glioma. | not yet recruiting | Phase 3 | 36 | Primo Biotechnology Co., LtdINDUSTRY | 1 | Jul 13, 2026 |
| clinicaltrials |
| NCT07698899 | A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS) | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07699172 | EEG-Guided Cognitive Function Preservation in Patients With Brain Tumors | not yet recruiting | N/A | 10 | Bo WangOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT02648997 | An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma | active not recruiting | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 4 | Jul 10, 2026 | clinicaltrials |
| NCT03919071 | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | active not recruiting | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2026 | clinicaltrials |
| NCT06712875 | MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas | recruiting | Phase 1 / Phase 2 | 27 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07678684 | A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma | recruiting | Phase 2 | 30 | HighField Biopharmaceuticals CorporationINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07694622 | Targeting MYC in High-Risk Medulloblastoma(MYCMB) | not yet recruiting | N/A | 35 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04485949 | A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma | active not recruiting | Phase 2 | 99 | ImvaxINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05700071 | MRS of Glioma Genomics(GLIOMRS) | recruiting | N/A | 110 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07689721 | ctDNA-Guided Intraventricular Therapy for CNS Malignancies(GUIDE-CNS) | not yet recruiting | N/A | 77 | Alireza MansouriOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT04638478 | PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI | active not recruiting | — | 67 | Maastricht Radiation OncologyOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06448286 | PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma | not yet recruiting | Phase 3 | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07687277 | 3D-ASL and TDD-MRI for True Progression and Pseudoprogression After Glioma Surgery(ASL-TDD) | active not recruiting | — | 75 | Lanzhou University Second HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05835687 | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors | active not recruiting | Phase 1 | 29 | St. Jude Children's Research HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07085325 | CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation | recruiting | — | 184 | St. Jude Children's Research HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04576117 | A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma | active not recruiting | Phase 3 | 300 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 572 | Nurix Therapeutics, Inc.INDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07025226 | Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease(Senolytics) | recruiting | Early Phase 1 | 30 | Mayo ClinicOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05720078 | UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3)(UNITED-3) | active not recruiting | N/A | 70 | Sunnybrook Health Sciences CentreOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06061809 | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | active not recruiting | Phase 2 | 34 | ImmunityBio, Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06388733 | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma | active not recruiting | Phase 3 | 450 | Ivy Brain Tumor CenterOTHER | 11 | Jul 1, 2026 | clinicaltrials |
| NCT06665373 | Fitness and Nutrition in Glioma | active not recruiting | N/A | 15 | NYU Langone HealthOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06805305 | DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | recruiting | Phase 2 | 180 | Diakonos Oncology CorporationINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07210632 | Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) | recruiting | Early Phase 1 | 38 | Eben RosenthalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07674095 | Assessment of a Large US EHR Database as Meeting FDA Fit-for-Purpose Requirements to Provide External Controls for Study BPM31510 in Participants With Glioblastoma | active not recruiting | — | 150 | BPGbioINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678138 | Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive Glioblastoma | not yet recruiting | N/A | 9 | Huanhu Hospital Affiliated to Tianjin Medical UniversityOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT05864976 | Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning | recruiting | — | 100 | Washington University School of MedicineOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07316101 | Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery | recruiting | N/A | 20 | West China HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07493447 | Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures | recruiting | Early Phase 1 | 30 | Eben RosenthalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07670455 | Brain Radiotherapy Imaging for High-grade Glioma Using Hypoxia Targeting Through Oxygen-Enhanced Response(BRIGHTER) | not yet recruiting | N/A | 25 | The Leeds Teaching Hospitals NHS TrustOTHER | 0 | Jun 30, 2026 | clinicaltrials |
| NCT02177578 | Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme | active not recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03510208 | Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | recruiting | Phase 1 / Phase 2 | 46 | Stanford UniversityOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06333899 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT06815029 | Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma | recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06861244 | Embryonal Tumor With Multilayered Rosettes(PNOC031) | recruiting | Phase 2 | 70 | University of California, San FranciscoOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07284628 | Vortioxetine for Newly Diagnosed Glioblastoma(ReVoGlio) | recruiting | Phase 2 | 78 | University of ZurichOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05009992 | Combination Therapy for the Treatment of Diffuse Midline Gliomas(PNOC022) | recruiting | Phase 2 | 360 | University of California, San FranciscoOTHER | 6 | Jun 26, 2026 | clinicaltrials |
| NCT05120284 | Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) | active not recruiting | Phase 2 | 40 | University of FloridaOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06157541 | T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma(TCaP) | active not recruiting | Phase 1 / Phase 2 | 58 | Queensland Institute of Medical ResearchOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03175432 | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | active not recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04573140 | A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)(PNOC020) | recruiting | Phase 1 | 28 | University of FloridaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06126588 | Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial(ELUMEN) | recruiting | Phase 2 | 28 | Central Hospital, Nancy, FranceOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06428045 | STARLITE for Unresectable High-Grade Gliomas(STARLITE) | recruiting | Phase 1 | 24 | University of MiamiOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668869 | TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0) | recruiting | N/A | 92 | Prof. Franciszek Lukaszczyk Memorial Oncology CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07670026 | Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression | recruiting | Phase 2 | 31 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 13, 2026source: clinicaltrials